To Be Discontinued Tablet Antiviral
Cobicistat Tablet · 339 days since initial FDA posting
Brand: TYBOST
FDA lists Cobicistat Tablet as To Be Discontinued (Gilead Sciences, Inc.).
No availability text on this FDA row.
Cobicistat Tablet: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Cobicistat Tablet
- Manufacturer
- Gilead Sciences, Inc.
- Dosage Form
- Tablet
- Presentation
- Tybost, Tablet, 150 mg (NDC 61958-1401-1)
- Package NDC
- 61958-1401-1
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Oct 7, 2025
- Last Updated
- Oct 7, 2025
- Therapeutic Category
- Antiviral
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons.
Nearby, Other Cobicistat Shortage Records
FDA reason on file: Gilead plans to sell through the end of February 2026. General shortage guidance lives on the tracker hub.